The global primary immunodeficiency market is expected to grow at a healthy CAGR of ~6% during the forecast period.
The global primary immunodeficiency market is expected to grow at a healthy CAGR of ~6% during the forecast period. The market growth can be primarily attributed to a host of factors, including advancements in molecular studies, rapid strides taken by next-generation sequencing technologies, DNA sequencing, and RNA sequencing. Research and development activities will continue to play a key role in boosting the prospects of the new primary immunodeficiency treatment and therapies. Companies operating in the current market landscape should ideally focus on the development of tailor-made primary immunodeficiency therapies to gain an edge.
Primary Immunodeficiency Market: Overview
- According to Transparency Market Research’s latest research report on the global primary immunodeficiency market for the historical period (2017–2018) and the forecast period (2020–2028), high prevalence of hypertension is anticipated to drive the global primary immunodeficiency market in the near future
- According to the report, the global primary immunodeficiency market was valued at US$ 5.7 Bn in 2019 and is projected to expand at a CAGR of ~6% from 2020 to 2028
Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3137
Government Approval for New Therapies for PIDD Treatment: A Key Driver
- On April 1, 2019, the U.S. Food and Drug Administration (FDA) approved ADMA Biologics’ Asceniv to treat primary humoral immunodeficiency disease (PIDD or PI) in adults and adolescents
- On Sep 14, 2016, the U.S. Food and Drug Administration (FDA) granted Shire approval for CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in adult and pediatric patients two years of age and older
- On October 5, 2018, Leadiant Biosciences, Inc. announced that the Food and Drug Administration (FDA) granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy (ERT) for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
- On September 12, 2014, Baxter International Inc. (2.20%) and Halozyme Therapeutics, Inc. (0.73%) announced that the U.S. Food and Drug Administration (FDA) approved Baxter’s subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA Immune Globulin Infusion 10% (Human) with recombinant human Hyaluronidase
- All the above mentioned products offer cost-effective treatment for PIDD and deliver full therapeutic dose of immune globulin to patients
- Therefore, such approvals increase the demand for primary immunodeficiency diseases treatment, leading to market growth
Request for Analysis of COVID19 Impact on Primary Immunodeficiency Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=3137
Gradual Increase in Incidence of Primary Immunodeficiency Diseases Globally
- Gradual rise in incidence rate of primary immunodeficiency diseases such as common variable immune deficiency, Ataxia Telangiectasia, and complement deficiencies drives the primary immunodeficiency disorder market
- Early diagnosis of PID is critical for preventing significant disease-associated morbidity and even mortality. The national surveys of PID conducted by the Immune Deficiency Foundation in the U.S. found that approximately 60% of patients with these disorders were not diagnosed until adulthood despite the fact that many reported serious or chronic health conditions prior to diagnosis, such as sinusitis, bronchitis, and pneumonia.
- According to an article in the Allergy, Asthma & Clinical Immunology, with the exception of IGA deficiency (prevalence = 1 in 300–500), PIDs are more frequent than the estimated prevalence of 1 in 1200 live births
- Advanced testing for detecting the presence or function of cellular proteins is carried out to confirm the diagnosis of PID. Moreover, testing for genetic causes is an important component of diagnosis. These are expensive and thus, ignorance can also lead to increase in prevalence and spread of the disease.
- According to an article in the Journal of Clinical Immunology, the population prevalence of diagnosed PID in the U.S. is 1 in 1,200 people. This translates into a population rate for diagnosed PID of 0.0863%. When applied to the U.S. population of 297,386,000 persons, this gives an estimate of approximately 250,000 persons with diagnosed PID in the U.S.
- Therefore, gradual increase in incidence rate would, in turn, drive the demand for PIDD treatment therapies, leading to market growth
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=3137
Lack of Adequate Reimbursement and High Treatment Cost Hindering PIDD Market Growth
- Reimbursement on the national health care system plays a key role in ensuring access to the therapies, but these are not always equally reimbursed in the different countries. For instance, treatment with intravenous or subcutaneous immunoglobulin G (IGG) is covered by the national health system in most countries in Europe. However, it is not consistently available in low- or mid-income regions of the world.
- Reimbursement policies also vary between different IG therapies and in some countries only one IG product is reimbursed. In some cases, reimbursement is based on the type of PI, meaning that in case of less severe PI, patients have to bear the cost of treatment on their own. Significant disparities in terms of reimbursement are also noticeable according to insurance plan options.
- Despite the proven effectiveness of intravenous immunoglobulin (IVIG), accessibility to treatment and reimbursement of treatment costs differ by country. IVIG is fully reimbursed by the government: the greatest challenge for treatment is accessibility to a treatment center. Private insurance usually does not provide reimbursement for regular treatment with IVIG for PIDD.
- Access to laboratory testing is generally limited or, if available, costs to cover testing are difficult. Some screening tests are covered by governmental health programs, but specialized diagnostic tests are typically not reimbursed.
- IGs are included in the World Health Organization List of Essential Medicines for both adults and children with PI. Several areas are considered by governments and regulatory authorities, which include appropriate supply of IGs on the national healthcare systems to ensure equal access for all individuals and also guarantee (appropriate) reimbursement of therapies.
Buy Primary Immunodeficiency Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=3137<ype=S
Rise in Number of Undiagnosed Patients Affecting Revenue Inflow
- Primary immunodeficiency patients remain undiagnosed or have a substantially delayed diagnosis with adverse results on morbidity and mortality
- Several studies state that approximately 10 million people suffer from PIDD across the world, whereas it is around 250,000 people in developed countries such as the U.S. However, thousands of children and adults remain undiagnosed or under-diagnosed. This acts as a restraint of the PIDD market not only in developed but also in emerging countries.
- Health consequences of an undiagnosed disease can include death and severe, life-threatening infections. Moreover, it is a loss of potential revenue for drug manufacturers and diagnostic companies, affecting the PIDD market growth opportunities. Companies should start promotional activities in collaboration with governments and providers (physicians) especially in emerging markets such as Brazil, China, India, Mexico, and Singapore.
- It is hypothesized that undiagnosed PIDD may burden both the patient with repeated infections and the healthcare system with significant service utilization
Primary Immunodeficiency Market: Competition Landscape
- This report profiles major players operating in the global primary immunodeficiency market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
- The global primary immunodeficiency market is moderately fragmented, with the presence of a few large players in the international market and numerous small players in regional markets. The top four to five players hold major share of the global primary immunodeficiency market.
- Prominent players operating in the global primary immunodeficiency market include
- Shire plc
- CSL Behring
- Kedrion Biopharma Inc
- Grifols, S.A
- Octapharma
- China Biologic Products Holdings, Inc
- Biotest AG,
- Sanquin,
- LFB SA
- The report on the global primary immunodeficiency market discusses individual strategies, followed by company profiles of manufacturers of primary immunodeficiency therapeutics. The ‘Competition Landscape’ section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global primary immunodeficiency market.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453